Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Jun 30, 2015 1:39pm

146 Views

Post# 23881709

RE:Next on the Agenda

Ron,

The Hepalink deal must close BY 7/26/15, not necessarily on 7/25/15. So if I read it correctly, closing could occur anytime between now and 7/26/15. Yes, more info on Phase III is highly anticipated. However, FDA approval is just one facet of the pending trial design. Europe and Asia are currently slated to be the major focus of the trial (of course more countries could be added). As of last word from Don, he wasn't sure if US (and FDA) would be involved in this trial. Also, the last day of Q2 is not over yet. Still a chance (though the minutes are ticking) for the rumored Q2 2015 orphan indication to be announce.

Best,

BDAZ

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale